Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinco Pharmaceutical HoldingsHKSE:06833 -0.60%44 Gross Margin % is 10.28% as of Dec. 2025, which is 21% below its 10-year median of 13.05. GuruFocus rates HKSE:06833 with a GF Score™ of 44/100 and a GF Value™ of HK$0.19 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 118 Medical Distribution companies, Sinco Pharmaceutical Holdings ranks worse than 68.64% on this metric.
HKSE:06833's Gross Margin % is ranked worse than 68.64% of 118
companies
in the Medical Distribution industry
Industry Median: 15.015
vs HKSE:06833: 10.65
Sinco Pharmaceutical Holdings had a gross margin of 10.28% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sinco Pharmaceutical Holdings had a gross margin of 10.28% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sinco Pharmaceutical Holdings Gross Margin % Related Terms
Sinco Pharmaceutical Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06833 vs MCK, COR, CAH: Gross Margin % Comparison
For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinco Pharmaceutical Holdings Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sinco Pharmaceutical Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sinco Pharmaceutical Holdings (HKSE:06833) has a Gross Margin % of 10.28% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Sinco Pharmaceutical Holdings and its competitors. This is 21% below median its historical median of 13.05. Over the past decade, Sinco Pharmaceutical Holdings' Gross Margin % has ranged from 10.63 to 23.19. According to the industry distribution chart, Sinco Pharmaceutical Holdings ranks #81 out of 118 companies in the Medical Distribution industry, placing it in the top 68.6%.
Is Sinco Pharmaceutical Holdings' Gross Margin % too high?
Sinco Pharmaceutical Holdings' current Gross Margin % of 10.28% is 21% below median its 10-year median of 13.05. Over the past 10 years, this metric has ranged from a low of 10.63 to a high of 23.19. The Medical Distribution industry median Gross Margin % is 15.02. Sinco Pharmaceutical Holdings' value of 10.28% is 31.5% below this industry median. Based on the distribution chart, Sinco Pharmaceutical Holdings ranks #81 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' Gross Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinco Pharmaceutical Holdings ranks #81 out of 118 companies for Gross Margin %. This places Sinco Pharmaceutical Holdings in the lower half of its industry. The industry median Gross Margin % is 15.02. Sinco Pharmaceutical Holdings' value of 10.28% is 31.5% below this benchmark. Historically, Sinco Pharmaceutical Holdings' own Gross Margin % has ranged from 10.63 to 23.19 over the past decade. While the company's 10-year median is 13.05 vs. the industry median of 15.02, Sinco Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 15.02, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinco Pharmaceutical Holdings's current Gross Margin % of 10.28% is 31.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sinco Pharmaceutical Holdings and its competitors. For the Medical Distribution industry, the median Gross Margin % is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinco Pharmaceutical Holdings's current Gross Margin % is 10.28%, which is 21% below median its own 10-year median of 13.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current Gross Margin % is 10.28%, which is 21% below median its 10-year median of 13.05 and 31.5% below the Medical Distribution industry median of 15.02. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current Gross Margin % is 10.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19.
GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:06833:
Gross Margin %: 10.28% (21% below median its 10-year median of 13.05)
GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
Industry Position: 31.5% below the Medical Distribution median (#81 of 118)
No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score
Get the complete analysis for HKSE:06833
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06833 has been successfully added to your 
